Determined to get to the bottom of health problems seemingly related to the ingestion of fluoroquinolone antibiotics, the U.S. Food and Drug Administration announced that two of its expert committees will hold a joint meeting about these medications that will be open to the public. The meeting will be held Nov. 5 from 8 a.m. to 6 p.m. at the FDA's Silver Spring, Md., campus.
There has been a procedural development in lawsuits filed against the makers of fluoroquinolone drugs, which are linked to serious nerve damage. A group of judges known as the U.S. Judicial Panel on Multidistrict Litigation centralized all of the federal litigation of this nature before a single judge Aug. 17. The judge is based at a federal trial court in Minnesota.
Since the U.S. Food and Drug Administration in August 2013 required fluoroquinolone drug labels to carry a warning about the risk of the possible rapid and permanent onset of peripheral neuropathy, a recent study showed that the risk is genuine. In the meantime, patients who were prescribed one of these medications and who were since diagnosed with peripheral neuropathy may want to discuss their legal options with an attorney - as many already have done.